阿拉曼丁-1-5的鉴定和特征,它是宁-血管素系统的新组成部分
Robson A S Santos1, Melissa Tainan Silva Dias2, Amanda de Sá Martins Bessa1
1INCT-Nanobiofar, Department of Physiology and Biophysics (R.A.S.S., A.S.M.B., C.F.B., M.F.I., F.A.S., S.C.A.G., L.R.-R., K.S.F., S.S., I.Z.L.F.F., U.F.V.-M., A.C.V.G., A.H.A.M., M.E., B.S., A.M., G.M., N.P.S., D.A.A.P., J.R.R., M.L.D.-P., D.M.-S., M.A.P.F., A.S.H., T.V.-B., S.G., M.F.L., M.J.C.-S.), Federal University of Minas Gerais (UFMG), Brazil.
Circulation research
|November 12, 2025
概括
阿拉曼丁-[1-5]是人类和动物循环中发现的氨酸-氨酸系统中新发现的. 这种通过不同组织中的各种机制表现出显著的降血压效应.
科学领域:
- 生物化学 生物化学
- 心血管生理学心血管生理学
- 内分泌学 在内分泌学.
背景情况:
- 胺-血管素系统 (RAS) 是一个关键的激素级联,调节血压和液体平衡.
- 阿拉曼丁是RAS中的,其潜在产物阿拉曼丁-[1-5],尚未完全表征.
- 了解新型RAS对于开发心血管疾病的新治疗策略至关重要.
研究的目的:
- 为了识别和描述循环中的阿拉曼丁-[1-5]的存在.
- 研究阿拉曼丁的生物活动和受体相互作用-[1-5].
- 阐明阿拉曼丁-[1-5]在血压调节和心血管功能中的作用.
主要方法:
- 使用先进的质谱技术 (MALDI/TOF/TOF,LC-MS/MS) 进行鉴定.
- 采用了一系列体外和体外模型,包括分离器官,细胞培养和动物研究 (常压和高血压大鼠,受体缺乏小鼠).
- 评估生理参数,如血压,心脏输出和心脏收缩率,以及受体结合测试.
主要成果:
- 在健康的人类和动物的循环中检测到阿拉曼丁-[1-5].
- 这种在自发高血压的老鼠中表现出显著的抗高血压作用,减少心脏输出量和内托普主义.
- 阿拉曼丁-[1-5]通过Mas,MrgD和AT2受体刺激了氧化的产生,MrgD在其心血管作用中发挥了关键作用.
结论:
- 阿拉曼丁-[1-5]是RAS中的一种新,具有强大的降血压特性.
- 它的作用机制在各个组织中各不相同,使其与传统的RAS通路区分开来.
- 这一发现为了解RAS信号和开发向治疗开辟了新的途径.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:33Hormonal Regulation
35.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
35.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:31Adrenergic Receptors: ɑ Subtype
2.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.6K